Bilir Sara Pinar, Ferrufino Cheryl P, Pfaller Michael A, Munakata Julie
Health Economics & Outcomes Research, 425 Market Street, 7th Floor, IMS Health, San Francisco, CA 94105, USA.
T2Biosystems, 101 Hartwell Ave, Lexington, MA 02421, USA.
Future Microbiol. 2015;10(7):1133-44. doi: 10.2217/fmb.15.29. Epub 2015 Apr 7.
This study estimates the cost-effectiveness and hospital budget impact of rapid candidemia identification using T2Candida, a novel diagnostic panel with same-day species-specific results.
MATERIALS & METHODS: A 1-year decision-tree model estimates hospital costs (2013 US$) and effects (candidemia-related deaths) for faster diagnostics versus blood culture (BC), accounting for disease prevalence, distribution of Candida species, test characteristics (sensitivity/specificity/time to result), antifungal medication and differential length-of-stay and mortality by appropriate treatment timing.
The model estimates a hospital with 5100 annual high-risk patients could possibly save $5,858,448 with T2Candida versus BC, a 47.6% decrease in candidemia diagnosis and treatment budget ($1149/patient tested), while averting 60.6% of candidemia-related mortality.
Hospitals may observe lower candidemia-related inpatient costs and mortality with rapid Candida diagnosis.
本研究评估了使用T2念珠菌（一种能在同一天给出菌种特异性结果的新型诊断试剂盒）快速鉴定念珠菌血症的成本效益和对医院预算的影响。
一个为期1年的决策树模型估计了与血培养（BC）相比，更快诊断方法的医院成本（2013年美元）和效果（念珠菌血症相关死亡），考虑了疾病患病率、念珠菌菌种分布、检测特征（敏感性/特异性/出结果时间）、抗真菌药物以及根据适当治疗时机的不同住院时间和死亡率。
该模型估计，一家每年有5100名高危患者的医院使用T2念珠菌相对于血培养可能节省5,858,448美元，念珠菌血症诊断和治疗预算降低47.6%（每位检测患者1149美元），同时避免60.6%的念珠菌血症相关死亡。
医院通过快速诊断念珠菌血症可能会降低与念珠菌血症相关的住院成本和死亡率。
